NYSE:MED - Medifast Stock Price, News, & Analysis

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast announced a quarterly dividend on Wednesday, December 12th. Investors of record on Friday, December 21st will be given a dividend of $0.75 per share on Thursday, February 7th. This represents a $3.00 annualized dividend and a dividend yield of 2.37%. The ex-dividend date is Thursday, December 20th. This is a positive change from Medifast's previous quarterly dividend of $0.48. View Medifast's Dividend History.

Medifast Inc (NYSE:MED) announced its quarterly earnings results on Tuesday, November, 6th. The specialty retailer reported $1.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.14. The specialty retailer had revenue of $139.20 million for the quarter, compared to analyst estimates of $125.20 million. Medifast had a return on equity of 43.45% and a net margin of 10.95%. The company's quarterly revenue was up 80.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.55 earnings per share. View Medifast's Earnings History.

Medifast is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Medifast.

Medifast updated its FY18 earnings guidance on Tuesday, November, 6th. The company provided EPS guidance of $4.45-4.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.47. The company issued revenue guidance of $492.5-497.5 million, compared to the consensus revenue estimate of $470.31 million.Medifast also updated its FY 2018 guidance to $4.45-4.50 EPS.

2 Wall Street analysts have issued 1-year price objectives for Medifast's stock. Their forecasts range from $249.00 to $249.00. On average, they anticipate Medifast's stock price to reach $249.00 in the next twelve months. This suggests a possible upside of 96.6% from the stock's current price. View Analyst Price Targets for Medifast.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medifast.

News coverage about MED stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medifast earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news stories about the specialty retailer a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an impact on the company's share price in the next few days.

Some companies that are related to Medifast include MCCORMICK & CO /SH (MKC), WANT WANT CHINA/ADR (WWNTY), Greencore Group (GNCGY), Farmer Bros (FARM), China Marine Food Group (CMFO) and Jammin Java (JAMN).

Medifast's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.16%), Vanguard Group Inc. (10.74%), Vanguard Group Inc (10.74%), Renaissance Technologies LLC (8.01%), Dimensional Fund Advisors LP (5.73%) and Acadian Asset Management LLC (3.57%). Company insiders that own Medifast stock include Charles P Connolly, Constance J Hallquist, Daniel R Chard, Glenn W Welling, Jeremy John Martin, Michael A Hoer, Michael C Macdonald, Ralph Rushton and Simon TP Ridgway. View Institutional Ownership Trends for Medifast.

MED stock was sold by a variety of institutional investors in the last quarter, including Teachers Advisors LLC, Man Group plc, TIAA CREF Investment Management LLC, Renaissance Technologies LLC, Acadian Asset Management LLC, Wells Fargo & Company MN, O Shaughnessy Asset Management LLC and Seizert Capital Partners LLC. Company insiders that have sold Medifast company stock in the last year include Charles P Connolly, Constance J Hallquist and Michael C Macdonald. View Insider Buying and Selling for Medifast.

MED stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., BlackRock Inc., AQR Capital Management LLC, Robeco Institutional Asset Management B.V., Robeco Institutional Asset Management B.V., SG Americas Securities LLC and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard, Glenn W Welling, Michael A Hoer and Simon TP Ridgway. View Insider Buying and Selling for Medifast.

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MED stock can currently be purchased for approximately $126.65.

Medifast has a market capitalization of $1.60 billion and generates $301.56 million in revenue each year. The specialty retailer earns $27.72 million in net income (profit) each year or $2.29 on an earnings per share basis. Medifast employs 399 workers across the globe.

The official website for Medifast is http://www.medifast1.com.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]